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Edited by Judit Ova´diAbstract Canavan disease is an autosomal-recessive neuro-
degenerative disorder caused by a lack of aspartoacylase, the
enzyme that degrades N-acetylaspartate (NAA) into acetate
and aspartate. With a view to studying the mechanisms underly-
ing the action of human aspartoacylase (hASP), this enzyme was
expressed in a heterologous Escherichia coli system and charac-
terized. The recombinant protein was found to have a mole-
cular weight of 36 kDa and kinetic constants Km and kcat of
0.20 ± 0.03 mM and 14.22 ± 0.48 s1, respectively. Sequence
alignment showed that this enzyme belongs to the carboxypepti-
dase metalloprotein family having the conserved motif
H21xxE24(91aa)H116. We further investigated the active site of
hASP by performing modelling studies and site-directed muta-
genesis. His21, Glu24 and His116 were identiﬁed here for the
ﬁrst time as the residues involved in the zinc-binding process.
In addition, mutations involving the Glu178Gln and Glu178Asp
residues resulted in the loss of enzyme activity. The ﬁnding that
wild-type and Glu178Asp have the same Km but diﬀerent kcat val-
ues conﬁrms the idea that the carboxylate group contributes
importantly to the enzymatic activity of aspartoacylase.
 2006 Published by Elsevier B.V. on behalf of the Federation of
European Biochemical Societies.
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Human aspartoacylase (hASP; EC 3.5.1.15) deﬁciency is
responsible for Canavan disease (CD), an autosomal recessive
form of leukodystrophy characterized by spongy degeneration
of the white matter in the brain [1], which leads to early death
[2]. hASP hydrolyzes N-acetylaspartic acid (NAA) into aspar-
tate and acetate. Although the pathogenesis of CD has not yet
been elucidated, the most recent hypothesis is that hASP par-
ticipates actively in the process of myelin synthesis by provid-
ing the NAA-derived acetate required for acetyl-CoA to be
synthesized, which is used in turn to synthesize the lipid com-
ponent of myelin [3]. CD therefore results from defectiveAbbreviations: CD, Canavan disease; hASP, human aspartoacylase;
CP, carboxypeptidase; SGD, succinylglutamate desuccinylase from
Chromobacterium violaceum; NAA, N-acetylaspartate
*Corresponding author. Fax: +33 491288440.
E-mail address: thierry.giardina@univ-cezanne.fr (T. Giardina).
0014-5793/$32.00  2006 Published by Elsevier B.V. on behalf of the Feder
doi:10.1016/j.febslet.2006.09.056myelin synthesis due to a shortage of NAA-derived acetate.
The biochemical marker generally used to diagnose this disor-
der is an abnormally high level of NAA in the cerebrospinal
ﬂuid and the urine owing to hASP deﬁciency [4,5]. CD is
caused by mutations aﬀecting the gene encoding hASP at the
17p13-ter site [6]. The prevalence is highest among Ashkenazi
Jews: in this population, the carrier frequency is 1 in 55–59 [7],
and two mutations, Y231X and E285A, account for 98% of the
CD alleles. The hASP gene contains ﬁve introns and six exons
encoding a 313-amino acid enzyme with a molecular weight of
approximately 36 kDa [8]. Based on the inhibitory eﬀects of
diisopropylﬂuorophosphate, a classic of serine proteases inac-
tivator, it has been suggested that aspartoacylase may be a ser-
ine hydrolase belonging to the esterase family [8], but no serine
consensus motif was found to be present in the primary struc-
ture. However, alignment studies showed that hASP contains
the conserved metal ion ligands occurring in the carboxypepti-
dase family [9]. hASP was recently cloned and expressed in a
heterologous Pichia pastoris expression system [10]. It was
established in this study that the glycosylation process is an
important factor contributing to the stability of the recombi-
nant enzyme; deglycosylation or mutations occurring at the
glycosylation site decreased both the stability and the catalytic
activity of the enzyme. In addition, the latter authors showed
that hASP contains one zinc atom per monomer.
In the present study, with a view to further investigating the
active site of hASP, a stable form of hASP was expressed using
the heterologous Escherichia coli expression system and puri-
ﬁed. Some speciﬁc residues putatively involved in Zn coordina-
tion in hASP were analyzed for the ﬁrst time. In addition, the
role of Glu178, the putative catalytic residue was studied. The
catalytic and metal coordination properties of wild-type and
mutant enzymes are interpreted here on the basis of a mole-
cular model for hASP.2. Materials and methods
2.1. Cloning of human aspartoacylase
The clone (#IRATp970H1144D) containing the complete open
reading frame of hASP was obtained from the RZPD German Re-
source Center for Genome Research (Berlin, Germany). The hASP
nucleotide sequence fused to an upstream GST sequence was cloned
using the Gateway system (Invitrogen). hASP cDNA was ﬁrst synthe-
sized in a PCR mixture, using the primers, 5 0-GGGGACAAGTTTG-
TACAAAAAAGCAGGCTTG CTGGTTCCGCGTGGATTCACT-
TCTTGTCACATTGCTGAAGAA-30 and 5 0-GGGGACCACTTT-
GTACAAGAAAGCTGGGTAAGCTGGAAGTGATTTCTAAT-3 0,
where the underlined sequence corresponds to the thrombin cleavage
site. Each primer (1 lM) was annealed to the matrix (50 ng) and bothation of European Biochemical Societies.
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polymerase (Invitrogen) in a linear extension reaction carried out by
PCR under the following conditions: 2 min denaturation at 95 C,
and 12 cycles of 30 s denaturation cycles at 95 C, 1 min 30 annealing
at 55 C, 3 min at 68 C, and 5 min extension at 68 C. PCR cycling
was performed in a Mastercycler gradient 5331 system (Eppendorf).
Full length PCR product was puriﬁed by electrophoresis in a 1% aga-
rose gel using the QIAquick Gel Extraction kit (Qiagen) and was in-
serted into a pDONR/Zeo entry vector using a PCR Cloning System
with the Gateway Technology kit (Invitrogen). Starting with this entry
clone, the hASP DNA construct was cloned into a pDEST15 expres-
sion vector to obtain the DNA for the GST fusion protein. The expres-
sion vector was used to transform BL21 DE3 cells (Invitrogen).
Transformants were selected on LB medium plates containing
50 lg ml1 ampicillin, and the sequence was conﬁrmed by DNA
sequencing, which was carried out using the dideoxychain-termination
procedure developed by Genome Express (Grenoble, France).
2.2. Site-directed mutagenesis
Mutations were introduced into the pDEST15-hASP plasmid using
the QuickChange XL site-directed mutagenesis kit (Stratagene Europe,
Amsterdam Zuidoost, The Netherlands). Two overlapping comple-
mentary oligonucleotides containing the corresponding nucleotide
changes were designed for each mutation (Table 1). Mutations were
conﬁrmed by DNA sequencing, which was carried out using the dide-
oxychain-termination procedure developed by Genome Express (Gre-
noble, France). Lastly, the plasmids were inserted into E. coli BL21
DE3 competent cells to induce the expression of the proteins required.
2.3. Protein expression and puriﬁcation
Expression and puriﬁcation of the wild-type and mutant proteins
were performed as previously described with slight modiﬁcations
[11]. Brieﬂy, bacterial lysis was carried out in a 10 mM Tris–HCl,
pH 8.0, buﬀer containing 1 mM EDTA, 150 mM NaCl, and
10 mg ml1 lysozyme (STE buﬀer). Digestion was carried out at 4 C
for 15 min. Cells were then sonicated for 1 min in STE containing
1 M DL-dithiothreitol and 10% Sarkosyl. After a 16000-rpm centrifu-
gation run, the supernatant was supplemented with 10% Triton X-100
and incubated for 30 min at room temperature. The resulting soluble
fraction was mixed with GST-agarose beads preequilibrated with
PBS. The fusion protein was ﬁrst cleaved from GST by incubating
the gel overnight with thrombin (20 U ml1 gel bed volume) at room
temperature, and the resulting beads were subsequently washed with
PBS buﬀer. The soluble fraction was used for the characterization pro-
cedures, while the remaining bound GST was released from the column
into a 20 mM reduced glutathione solution containing 50 mM Tris–
HCl buﬀer, pH 8.0.
2.4. Enzyme activity
The hASP activity was measured with the procedures described by
Fields [12] for quantifying protein amino groups using trinitrobenzene-
sulfonic acid (TNBS). hASP was incubated with 2 mM N-acetyl-L-
aspartate in a 50 mM HEPES, pH 7.4, at 37 C for 15 min (total
reaction volume 125 ll). The reaction was stopped by adding 125 llTable 1
Oligonucleotides used for site-directed mutagenesis
Mutant Sequences
His21Ala A: ATCTTTGGAGGAACCgcTGGG
B: GGTTAGCTCATTCCCAgcGGT
Glu24Ala A: GGAACCCATGGGAATGcGCTA
B: AATACTCCGGTTAGCgCATTC
His116Ala A: ATT ATT TTT GACCTTgcCA
B: GTTAGAGGTGGTGTTGgcAAG
Glu178Asp A: TATCCTGTGGGTATAgAcGTT
B: AGGCTGAGGACCAACgTcTAT
Glu178Gln A: TATCCTGTGGGTATAcAAGTT
B: GGCTGAGGACCAACTTgTATAof a 0.1 M sodium borate solution, pH 10.0, containing 5 ll TNBS
(1 M in water). After a 5-min incubation step, the reaction was stopped
with 500 ll of a 1.5% 0.1 M sodium sulﬁte solution, containing dibasic
sodium phosphate 98.5%, 0.1 M and 200 ll of the resulting mixture
was transferred to a microtitre plate and measured at 420 nm. One unit
of enzyme activity was deﬁned as the amount of protein releasing
1 lmol of aspartate per minute. The Michaelis–Menten constants were
measured under the same conditions with substrate concentrations
ranging from 0.1 to 0.8 mM. The kinetic parameters were calculated
using the weighted nonlinear squares regression analysis method with
the Graﬁt software program (Biosoft, Cambridge, UK).
2.5. Polyacrylamide gel electrophoresis, protein determination and
N-terminal sequencing
SDS–PAGE was performed in 12% (w/v) polyacrylamide gel as de-
scribed by Laemmli [13] in the presence of 2% SDS under reducing
conditions. Protein concentration was determined using Bradford’s
method with bovine serum albumin as the standard [14]. N-terminal
amino acid sequencing of the Ponceau red-stained protein was per-
formed after electro-transfer onto a polyvinyldene diﬂuoride mem-
brane as described previously [15].
2.6. Sequence alignment and homology modelling of hASP
A molecular model for the hASP was constructed using atomic coor-
dinates based on the known structure of the succinylglutamate desuc-
cinylase from Chromobacterium violaceum (SGD) (PDB entry 1YW4)
[16]. The sequence of hASP (1–200) was aligned with the SGD using
the CLUSTALW v. 1.74 program [17]; the structure-based sequence
alignment was reﬁned by hand when necessary. The modelling of the
hASP structure was performed using Swiss Model (http://www.
expasy.ch/swissmod/SWISS-MODEL.html) and viewed using Swiss
PDB-Viewer (http://www.expasy.ch/spdbv/) [18,19].3. Results
3.1. Alignment analysis
Based on statistically signiﬁcant sequence similarities ob-
served between the aspartoacylase and Zn-Carboxypeptidase
families using the PSI-Blast program, Makarova and Grishin
[9] concluded that hASP is a Zn-dependent hydrolase. The
resulting alignment (Fig. 1) shows well conserved substrate-
binding and Zn-binding determinants. The zinc-consensus se-
quence in the carboxypeptidase family is modelled by the short
motif – HxxE and the His in the long sequence LHGGX, 95–
135 residues from the C terminal to this motif [20,21]. The
three structurally equivalent zinc ligands His69, Glu72 and
His196 present in the carboxypeptidase A (CPA) and His56,
Glu59 and His149 in the SGD correspond to the three zinc
ligands His21, Glu24 and His116 present in the LHNTT motifCodon change
AATGAGCTAACC CATﬁ GCT
TCCTCCAAAGAT-
ACCGGAGTATTT GAGﬁ GCG
CCATGGGTTCC
ACACCACCTCTAAC CACﬁ GCC
GTCAAAAATAAT
GGTCCTCAGCCT GAAﬁ GAC
ACCCACAGGATA
GGTCCTCAGCC GAAﬁ CAA
CCCACAGGATA
Fig. 1. Comparisons between the amino acid sequences of three aspartoacylases and carboxypeptidases, using the CLUSTAL W v. 1.74 [16]. Numbers
on the right indicate the position of the last residue, while dashes stand for gaps introduced into the sequences in order to achieve maximum
alignment. Identical and highly similar residues are shown in black and grey, respectively. The () indicates the catalytic residue present in
carboxypeptidase A, which is conserved in hASP. The Zinc-binding motif present in the carboxypeptidase A, which is indicated by a dark circle (d),
is also conserved in hASP. hASP: 1168340, human aspartoacylase, Homo sapiens; bASP: 1168339, aspartoacylase, Bos taurus; ASP-Synochcystis:
1652315, Synechocystis sp., aspartoacylase; SGD-Chromobacterium: 61680842, succinylglutamate desuccinylase, Chromobacterium violaceum; CP
A-b: 494937, Carboxypeptidase A, Bos taurus; CP E-h: 105546, carboxypeptidase E, Homo sapiens.
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number of amino acids present between the short and long mo-
tifs was also applied in the model. The 123 and 89 amino acid
long spacers present in CPA and SGD, respectively, were also
well correlated with the 91-amino acid spacer occurring in the
hASP sequence. We therefore suggested that hASP may be a
zinc metalloenzyme, in which the zinc ion(s) might be coordi-
nated via a metal centre consisting of His21, Glu24 and
His116. Based on the sequence alignment, we also postulated
that the catalytic residue, namely Glu270 in CPA and
Glu214 in SGD, might correspond to the Glu178 present in
the hASP enzyme.
3.2. Molecular modelling of hASP
No X-ray crystallographic structures of aspartoacylases are
available so far. In order to design catalytic and zinc-binding
mutant ligands for hASP, a molecular model for the humanenzyme was generated using the SGD as a template, which
aligned more closely than CPA with the hASP sequence. The
active site architectures of the hASP model and the three-
dimensional structure of the SDG are very similar. The puta-
tive residues coordinating the zinc atom His21, Glu24 and
His116 were located at atomic distances (<3 A˚) compatible
with the formation of the hydrogen bonds required for the
relay charge system to occur (Fig. 2). The spatial organisation
of these residues conﬁrms the validity of the proposed model,
since the chemical make-up of the residues that coordinate the
zinc atom is usually conserved among the members of the
carboxypeptidase family [22].
3.3. Expression and puriﬁcation of hASP wild-type and mutant
enzymes
Expression of recombinant hASP was observed in both the
total bacterial extract and the cytoplasmic extract upon
Fig. 2. Molecular model for the active site of human hASP. The
enzyme is colored in light gray, the zinc ion in yellow, His21 and
His116 in blue, Glu24 in red and Glu178 in green.
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ing to recombinant GST-hASP was not present in the absence
of IPTG (data not shown). Recombinant hASP was puriﬁed to
homogeneity by performing single-step aﬃnity chromatogra-
phy (GSTrap), followed by thrombin digestion. Pure mono-
meric hASP, corresponding to a molecular mass of 36 kDa,
was obtained on denaturing and reducing gel. The correct
cleavage and the identity of hASP were conﬁrmed by checking
the NH2-terminal amino acid sequence of the protein resulting
from thrombin digestion. The sequence GFTSCH obtained
was in complete agreement with the expected sequence, where
the amino acid residues GF and TSCH corresponded to the
sequence after thrombin digestion and the NH2-terminal
sequence of the expressed hASP, respectively. The overall1 2 3 4 5 6
36 kDa 
Fig. 3. SDS–PAGE of the recombinant hASP wild-type enzyme and
mutants. Lane 1, wild-type hASP. Lanes 2–6, His21Ala, Glu24Ala,
His116Ala, Glu178Asp and Glu178Gln mutants, respectively.
Table 2
Kinetic parameters of wild-type enzymes and mutants
Enzyme Speciﬁc activity (U/mg) kcat (s
1
WT 1557 ± 53 14.22 ±
Glu178Asp 300 ± 10 1.48 ±
Glu178Gln ND nd
His21Ala ND nd
Glu24Ala ND nd
His116Ala ND nd
ND: not detected, nd: not determined. hASP activity was determined usingyield of puriﬁed soluble hASP was about 1 mg l1 of cul-
ture medium, and the speciﬁc activity was found to be
1557 ± 53 U mg1 when NAA was used as the substrate. This
was ﬁnally taken to be a high enough value for investigating
the role of the putative Zn ligands His21, Glu24 and His116
and the putative catalytic residue Glu178 by performing site-
directed mutagenesis. Using the procedure described in Mate-
rial and Methods Section, plasmids corresponding to the
mutants were constructed and sequenced to conﬁrm the
nucleotide substitution at the mutation site. After the trans-
formation of E. coli BL21, the mutants were successfully
expressed in the soluble fraction. As shown in Fig. 3, the
mutant and wild-type enzymes had similar migration rates
and a molecular mass of 36 kDa. However, the overall yield
of puriﬁed mutant was lower compare to the wild-type’s one
(about 50–100 lg l1 of culture medium).
3.4. Chemical modiﬁcations
Recombinant hASP form hydrolyzed NAA but not the acyl-
ase I substrate Ac-Met. A number of selected chemicals includ-
ing the serine protease inhibiting reagent (PMSF), two
chelating agents (EDTA and 1,10-phenanthroline) and the
imidazole modifying reagent (DEPC) were tested to determine
their eﬀects on hASP activity. DEPC (5 mM) and the two che-
lating reagents (1,10-phenanthroline and EDTA) were found
to be equally eﬃcient concentration-dependent inhibitors.
However, PMSF was not able to completely inhibit the enzyme
activity, even at high concentrations (data not shown).
3.5. Enzymatic characterization of hASP mutants
Based on the sequence alignment and the structural model
(Fig. 2), which suggest that the metal is chelated by residues
His21, Glu24 and His116, we designed and produced mutants
for each of these three amino acids (His21-Ala, Glu24-Ala and
His116-Ala) (Table 2). Side group modiﬁcations functionally
impaired the enzyme because no activity was detected, even
with larger amounts of protein.
In order to determine the role of Glu178 in the catalytic pro-
cess, two diﬀerent mutants were designed and expressed.
Replacing Glu178, the putative active site nucleophile, by a
Gln residue dramatically aﬀected the enzymatic activity, which
was completely lost. This loss of activity was probably due to
the inability of Gln178 to act as the active site nucleophile/
leaving group. However, the Glu178Asp mutant displayed
residual activity when NAA was used as the substrate. The kcat
decreased some 10-fold relative to native hASP, and the bind-
ing behaviour (as indicated by the Km values) was not dis-
turbed, despite the increase in the length of the enzyme
nucleophile side chain (Table 2).) Km (mM) kcat/Km(s
1 mM1)
0.48 0.24 ± 0.04 59.25
0.19 0.22 ± 0.08 6.72
nd nd
nd nd
nd nd
nd nd
NAA as the substrate.
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This is the ﬁrst study to be carried out on the active site of
hASP, the enzyme involved in Canavan disease. The data ob-
tained here made it possible to identify the zinc binding ligands
and the catalytic residue involved. Using sequence alignment
methods, we observed that His21, Glu24 and His116 are per-
fectly aligned with the amino acids responsible for Zn binding
to the carboxypeptidase family. The carboxypeptidase en-
zymes’ coordination motif involves a histidine residue and a
glutamic acid located in the HxxE sequence, as well as another
histidine located 95–135 amino acids from the Glu residue.
This structural arrangement also occurs in the hASP sequence
and corresponds to the H21GNE24 and H116 at 91 amino acids
from Glu24. In addition, the molecular model developed for
hASP showed that the spatial organisation of these residues
is the same as that occurring in CPA. The inter-atom distances
between the ligands and the Zn atom (<3 A˚) are in good agree-
ment with a tetrahedric structure known to stabilize the metal
[22]. It is worth noting that Glu178, the putative catalytic res-
idue, is located in the vicinity of the Zn metal site. hASP
seemed likely to be a metalloenzyme. To conﬁrm this hypo-
thesis, a biochemical approach was used and wild-type and
diﬀerent hASP mutant enzymes were expressed using the
E. coli system and puriﬁed in one step. The yield obtained with
the wild-type enzyme was approximately 1 mg per litre of cell
culture. The wild-type enzyme was stable at 4 C for several
days, contrary to what was reported to occur by Moore
et al. [23] and Namboodiri et al. [24]. The Km determined in
this study was comparable to that reported by other authors,
but the kcat was 200-fold higher than that obtained by Moore
et al. [23]. The expression system we established with GST-
fusion tag and the use of low temperature during induction
allowed better folding behaviour of recombinant hASP, which
increased its solubility.
Paranitrophenol acetate, an ester classically hydrolyzed by
serine proteases, was not hydrolyzed by hASP. The serine pro-
tease speciﬁc reagent PMSF slightly decreased the enzyme
activity even at the high concentrations usually used to induce
complete inhibition. The active site of wild-type hASP was
investigated using chemical modiﬁcations. Our results clearly
showed that the enzyme was inhibited by the two chelating re-
agents EDTA and 1,10-phenanthroline and by the histidine
speciﬁc reagent DEPC. One Zn atom was found here to occur
per monomer, which conﬁrms the data recently obtained by
Le Coq et al. [10], with the enzyme expressed in P. pastoris.
Lastly, the lack of activity observed with His21Ala, Glu24Ala
and His116Ala mutants deﬁnitely conﬁrmed that hASP is a
metalloenzyme and enabled us to identify the residues respon-
sible for Zn coordination for the ﬁrst time.
As hASP belongs to the carboxypeptidase family of metal-
loenzymes [9], the idea that a carboxylic residue may be in-
volved in the catalysis seemed to be worth investigating. As
suggested in the case of Glu270 in CPA, another member of
the carboxypeptidase family, it seemed likely that Glu178 in
the human enzyme might be involved in the process of cata-
lysis. In the present study, to determine the catalytic role
of Glu178, two mutants were constructed and expressed,
namely Glu178Gln and Glu178Asp. Although the modiﬁca-
tion of Glu178 consistently decreased the catalytic activity, it
is worth noting that Glu178Gln is totally inactive, whereas
Glu178Asp showed a 20% residual activity and a 10-folddecrease in the kcat value. This result, along with sequence
comparisons with CPA and the results of our molecular
modelling studies, led to the conclusion that the catalytic activ-
ity of hASP requires the presence of the carboxylate group and
that Glu178 should be the catalytic residue in this enzyme.
In conclusion, the results of the present study show that the
E. coli expression system provides a suitable means of produc-
ing stable wild-type hASP and mutants. The data obtained
here clearly show that hASP is a metalloenzyme and not a ser-
ine protease. The ligands His21, Glu24 and His116 were found
to be deﬁnitely involved in the Zn coordination process. In
addition, Glu178 was identiﬁed as the most probably catalytic
residue. Although His21 and Glu24 are known to be residues
involved in Canavan disease [24,25], His116 and Glu178 are
not in the list of known mutations, and their identiﬁcation as
residues contributing importantly to hASP activity should be
useful for diagnosis in populations at risk. Future studies on
the hASP enzyme’s crystal structure could lead to a better
understanding of the physiopathology of Canavan disease
and the development of more eﬃcient methods for hASP gene
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